FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.
What happened
FDA inspected Lex Inc.'s drug manufacturing facility in Medley, Florida, from February 13 to February 28, 2023. The agency found significant current good manufacturing practice (CGMP) violations, including inadequate quality unit oversight, missing identity testing for glycerin and propylene glycol at risk of diethylene glycol (DEG) and ethylene glycol (EG) contamination, incomplete process validation, unqualified equipment, weak laboratory data controls, and inadequate scale calibration. FDA reviewed the firm's March 22, 2023 response and found it inadequate.
What FDA found
The quality unit failed to oversee drug manufacturing, approve or reject components and products, review records, and ensure CGMP compliance.
21 CFR 211.22The firm did not adequately test incoming components, including identity testing for glycerin and propylene glycol at risk of DEG/EG contamination, and did not qualify suppliers.
21 CFR 211.84(a), 211.84(d)(1), 211.84(d)(2)The firm lacked adequate written production and process control procedures and had incomplete process validation studies.
21 CFR 211.100(a)Manufacturing equipment was not qualified, laboratory computer systems allowed uncontrolled data changes, and production scales were not adequately calibrated.
21 CFR 211.68(a) and (b)
What FDA wants
FDA tells Lex to provide a comprehensive assessment and remediation plan covering its quality unit, component testing, supplier qualification, process validation, equipment qualification, calibration, and data integrity, including risk assessments and recalls for any DEG/EG-contaminated lots. FDA also strongly recommends engaging a qualified CGMP consultant; the letter does not state a response deadline.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- retailers and distributors of pediatric OTC cough and cold products
- suppliers and contract labs testing glycerin or propylene glycol
This is a summary. Read the original letter on fda.gov.